GLP-1 Medication Adoption Reshapes Bar Formulation
Rapid adoption of GLP-1 weight-management medications, with tens of millions of active US prescriptions by 2025 based on manufacturer disclosures, is reshaping snack bar demand toward smaller, more protein-dense formats suited to appetite-suppressed consumers who eat less overall but still want a portable, nutrient-complete option between infrequent meals. Several manufacturers have launched dedicated GLP-1-adjacent product lines since 2024, positioning smaller bars with higher protein density per calorie against the category's traditional larger, carbohydrate-forward formats. This shift is genuinely new demand rather than a repositioning of existing buyers, according to manufacturer-disclosed category research.
Market Impact: Captures over 45% of category growth








